BioSpace News Archive

Lantern Pharma Inc. today announced that it will present preclinical data on the potency of Lantern’s drug candidate LP-284 for mantle cell lymphoma (MCL) and several other non-Hodgkin’s lymphomas at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, Sept. 28 – Oct. 1, 2022, in Houston, TX.

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the Virtual Investor Innovations in Oncology – Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) Event on Wednesday, September 28, 2022 at 1:00 PM ET.

The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital today announced it received a $10 million donation from The Blue Bird Circle.

Evofem Biosciences (OTCPK: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate).

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.

Athersys, Inc. announced today that it has entered into amended agreements to extend the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022, among other changes, and to issue additional warrants to the same warrant holder, a healthcare-focused U.S. institutional investor.

CANbridge Pharmaceuticals, Inc. announced that it will be presenting data from the CAN106 Phase 1 trial in healthy volunteers at two conferences. CAN106 is under development for paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases and is currently in a Phase 1b/2 study in patients with PNH in China.

NervGen Pharma Corp., a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced today that the Board of Directors and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & Chief Executive Officer and a member of the Board, effective immediately.

Today, the U.S. Food and Drug Administration issued a draft guidance that, when finalized, will provide the agency’s perspective on the ethical considerations for including and protecting children in clinical trials.

The global Electrocardiograph market size was estimated at USD 9.2 billion in 2021 and is expected to surpass around USD 21.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 10% during the forecast period 2022 to 2030.